论文部分内容阅读
目的:了解脱氧核苷酸钠在肝病辅助治疗中致不良反应的特点及影响因素,为临床合理用药提供参考。方法:对某院2009-2015年收集到的29例脱氧核苷酸钠作为肝病辅助用药致ADR报告进行分析,包括患者的基本概况、用药剂量及溶媒、联合用药情况、ADR发生时间及持续时间、ADR累及系统-器官和主要临床表现、ADR的治疗及转归等,并用非条件Logistic回归进行危险因素分析。结果:29例ADR中,女性患者较多(65.52%),平均年龄(49.72±10.31)岁;ADR大部分发生在首次给药后,最快为用药后即刻出现,最慢为用药2周后;以变态反应最为常见(48.28%);ADR经处理后均治愈或停药后自愈。经统计分析,患者的年龄、体质量、性别、是否第一次用药、既往药物过敏史等均不会影响脱氧核苷酸钠不良反应的发生。结论:患者使用脱氧核苷酸钠注射液时均应严格按说明书,并严密监测患者体征及症状。临床中应重视脱氧核苷酸钠注射液致ADR的监测及报告工作。
Objective: To understand the characteristics and influencing factors of adverse reactions caused by deoxynucleate sodium in the adjuvant treatment of liver disease, and to provide a reference for clinical rational drug use. Methods: A total of 29 ADN cases collected from a hospital from 2009 to 2015 were analyzed as ADRs for liver disease, including the basic situation of the patients, dosage and vehicle, drug combination, duration and duration of ADR , ADR involved system-organ and its main clinical manifestations, treatment and outcome of ADR, etc., and analyzed the risk factors by using unconditional Logistic regression. Results: In 29 ADR cases, there were more female patients (65.52%) and mean age (49.72 ± 10.31) years old. Most ADR occurred immediately after the first administration, ; The most common allergic reaction (48.28%); ADR after treatment were cured or discontinued after healing. The statistical analysis, the patient’s age, body mass, gender, whether the first medication, previous drug allergy history will not affect the occurrence of adverse reactions of sodium deoxynucleotide. Conclusion: Patients should use deoxynucleotide sodium injection strictly in accordance with the instructions, and closely monitor the signs and symptoms of patients. In clinic, attention should be paid to the monitoring and reporting of ADR caused by deoxynucleotide sodium injection.